Ultragenyx Pharmaceutical
RARE
14.89
+0.43
+2.97%
Ultragenyx Pharmaceutical
US · RARE
#3012 by market cap
Listed 1970
14.89
+0.43
+2.97%
Live - 5344 symbols - heartbeat 25s ago
· 2026-10-08 07:08
Pre-market
14.63
-1.73%
After-hours
14.85
-0.27%
Overnight
14.89
0.00%
- Market cap
- 1.47B
- P/E (TTM)i
- -2.55
- P/Bi
- -5.04
- EPSi
- -5.83
- Div yieldi
- 0.00%
- 52W posi
- 8%
Reader sentiment
Are you bullish or bearish on RARE?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- Total institutional ownership rose 0.1 percentage points.
Institutional ownership
- Held by institutions
- 110.53% +0.14pp
- Institutions
- 385
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund66.69%
Hedge Fund32.34%
Public Company4.63%
VC/PE Fund4.16%
Individual/Insider3.60%
Private Company1.56%
Insurance Company0.46%
Government Pension Fund0.34%
Family Office/Trust0.26%
Top holders as of 2026-06-30
BlackRock
10.84% · 10.65M sh
RTW Investments, LP
7.93% · 7.80M sh
Vanguard Portfolio Management, LLC
6.91% · 6.79M sh
AQR Capital Management
6.65% · 6.53M sh
State Street Global Advisors
6.27% · 6.16M sh
Vanguard Capital Management, LLC
5.05% · 4.97M sh
Two Sigma Investments, LP
3.68% · 3.62M sh
Sands Capital Management, LLC
3.21% · 3.16M sh
Jacobs Levy Equity Management Inc
2.99% · 2.94M sh
Frontier Capital Management
2.90% · 2.85M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 30 buys · 20 sells
| Name | Role | Stake |
|---|---|---|
| Emil Kakkis | Chief Executive Officer | 2.80% |
| Thomas Kassberg | Chief Business Officer & Executive VP | 0.24% |
| Dennis Huang | Chief Technical Operations Officer & Gene Therapy Operations and Executive VP | 0.10% |
| John Pinion | Chief Quality Operations Officer & Executive VP of Translational Sciences | 0.09% |
| Erik Harris | Executive Vice President | 0.06% |
| Eric Crombez | Chief Medical Officer & Executive VP | 0.05% |
| Karah Parschauer | Chief Legal Officer & Executive VP | 0.04% |
| Daniel Welch | Independent Non-Executive Chairperson | 0.03% |
| Michael Narachi | Independent Director | 0.03% |
| Theodore Huizenga | Senior VP, Corporate Controller & Principal Accounting Officer | 0.03% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-14 | Theodore Huizenga | Senior VP, Corporate Controller & Principal Accounting Officer | Open Market Disposition | -1,283 | $13.57 |
| 2026-09-02 | Theodore Huizenga | Senior VP, Corporate Controller & Principal Accounting Officer | Open Market Disposition | -161 | $13.99 |
| 2026-08-02 | Howard Horn | Chief Financial Officer | Open Market Disposition | -4,696 | $24.92 |
| 2026-08-02 | Karah Parschauer | Chief Legal Officer & Executive VP | Open Market Disposition | -1,900 | $24.92 |
| 2026-06-30 | Howard Horn | Chief Financial Officer | Open Market Disposition | -4,698 | $33.13 |
| 2026-06-14 | Corazon Sanders | Independent Director | Open Market Disposition | -2,000 | $25.05 |
| 2026-06-14 | Karah Parschauer | Chief Legal Officer & Executive VP | Open Market Disposition | -1,899 | $24.62 |
| 2026-05-31 | Howard Horn | Chief Financial Officer | Open Market Disposition | -4,653 | $23.77 |
| 2026-05-17 | Shehnaaz Suliman | Independent Director | Open Market Disposition | -5,740 | $25.12 |
| 2026-05-13 | Daniel Welch | Independent Non-Executive Chairperson | Other Acquisition | +7,751 | -- |
| 2026-05-13 | Daniel Welch | Independent Non-Executive Chairperson | Other Derivative Acquisition | +14,058 | $25.80 |
| 2026-05-13 | Matthew Fust | Independent Director | Other Acquisition | +7,751 | -- |
| 2026-05-13 | Matthew Fust | Independent Director | Other Derivative Acquisition | +14,058 | $25.80 |
| 2026-05-13 | Shehnaaz Suliman | Independent Director | Other Acquisition | +7,751 | -- |
| 2026-05-13 | Shehnaaz Suliman | Independent Director | Other Derivative Acquisition | +14,058 | $25.80 |
| 2026-05-13 | Deborah Dunsire | Independent Director | Other Acquisition | +7,751 | -- |
| 2026-05-13 | Deborah Dunsire | Independent Director | Other Derivative Acquisition | +14,058 | $25.80 |
| 2026-05-13 | Corazon Sanders | Independent Director | Other Acquisition | +7,751 | -- |
| 2026-05-13 | Corazon Sanders | Independent Director | Other Derivative Acquisition | +14,058 | $25.80 |
| 2026-05-13 | Michael Narachi | Independent Director | Other Acquisition | +7,751 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:08:01 · For reference only, not investment advice and not tailored to your situation.